Bayer
Bayer Prepares for Critical Challenges Amid Xarelto Decline
Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25
Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion
Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition
Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics
Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor
Bayer’s Q3 Earnings Plummet 37%, CEO Urges Patience Amid Performance-Boosting Strategy
Bayer, Q3 earnings, decline, CEO Bill Anderson, performance-boosting strategy, pharmaceuticals, crop science, generics, Xarelto, Nubeqa, Kerendia.
Bayer and Dewpoint Therapeutics Collaborate on Dilated Cardiomyopathy Program with $424 Million Deal
Bayer, Dewpoint Therapeutics, Dilated Cardiomyopathy, DCM, Pharmaceutical Deal
Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees
Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction
Pharmaceutical Giants J&J and Bayer Announce Layoffs of Nearly 300 Employees in New Jersey
Johnson & Johnson, Bayer, layoffs, New Jersey, pharmaceutical industry, job cuts
Big Pharma’s Layoff Wave Continues in New Jersey: J&J and Bayer Announce Significant Job Cuts
Big Pharma layoffs, New Jersey, Johnson & Johnson, Bayer, pharmaceutical industry restructuring
Biopharma Leaders Navigate AI ‘Hype Cycle’: Bayer, Daiichi Sankyo, and argenx Share Insights on AI Implementation in Marketing
AI in biopharma marketing, Bayer, Daiichi Sankyo, argenx, AI implementation, biopharma industry, AI hype cycle
Bayer Seeks to Broaden Nubeqa’s Use in Prostate Cancer with Chemotherapy-Free Treatment Option
Nubeqa, Bayer, prostate cancer, chemotherapy-free, label expansion, ARANOTE trial, darolutamide, androgen deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC)